Drugs / BAY1862864
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02581878 | Nov 2015 → Nov 2019 | non-Hodgkin lymphoma | Bayer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 1862864 | “BAY 1862864 is an α-particle emitting 227Th-labeled CD22-targeting antibody.” PMID 33887152 ↗ Apr 2021 |
| Route | Intravenous | “BAY 1862864 intravenous injections were administered” PMID 33887152 ↗ Apr 2021 |
| Target | CD22 | “BAY 1862864 is an α-particle emitting 227Th-labeled CD22-targeting antibody.” PMID 33887152 ↗ Apr 2021 |